Literature DB >> 2661101

Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

W E Evans1, M V Relling.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2661101     DOI： 10.2165/00003088-198916060-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  49 in total

1.  Drug dosage and remission duration in childhood lymphocytic leukemia.

Authors:  D Pinkel; K Hernandez; L Borella; C Holton; R Aur; G Samoy; C Pratt
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

2.  Blood levels of chemotherapeutic agents and clinical outcome.

Authors:  J R Bertino
Journal:  J Clin Oncol       Date:  1987-07       Impact factor: 44.544

3.  Average relative dose intensity and the impact on design of clinical trials.

Authors:  W M Hryniuk
Journal:  Semin Oncol       Date:  1987-03       Impact factor: 4.929

4.  Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

Authors:  Y M Rustum; H D Preisler
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

5.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

Authors:  P Carde; F R MacKintosh; S A Rosenberg
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

Review 6.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

7.  Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU.

Authors:  G Milano; P Roman; R Khater; M Frenay; N Renee; M Namer
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

Review 8.  Dose-response in the treatment of breast cancer: a critical review.

Authors:  I C Henderson; D F Hayes; R Gelman
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

9.  Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.

Authors:  W E Evans; P R Hutson; C F Stewart; D A Cairnes; W P Bowman; G Rivera; W R Crom
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

10.  Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.

Authors:  J A Goldberg; D J Kerr; N Willmott; J H McKillop; C S McArdle
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640
View more
  26 in total

1.  Metabolism of epirubicin to glucuronides: relationship to the pharmacodynamics of the drug.

Authors:  J Robert; M David; C Granger
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Tackling the problems of tumour chemotherapy by optimal drug scheduling.

Authors:  Ambili Remesh
Journal:  J Clin Diagn Res       Date:  2013-05-31

Review 3.  Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.

Authors:  Neil S Horowitz; Alexi A Wright
Journal:  Gynecol Oncol       Date:  2015-04-12       Impact factor: 5.482

Review 4.  Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

Authors:  Milly E de Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Genetic polymorphisms of CYP2C8 in the Czech Republic.

Authors:  Kristina Pechandova; Helena Buzkova; Olga Matouskova; Frantisek Perlik; Ondrej Slanar
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-07

6.  Molecular design and synthesis of self-assembling camptothecin drug amphiphiles.

Authors:  Andrew G Cheetham; Yi-An Lin; Ran Lin; Honggang Cui
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

7.  Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.

Authors:  Rajesh R Kaldate; Abebe Haregewoin; Charles E Grier; Stephanie A Hamilton; Howard L McLeod
Journal:  Oncologist       Date:  2012-03-01

Review 8.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

9.  Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.

Authors:  Ahmed F Hawwa; Paul S Collier; Jeff S Millership; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-09-23       Impact factor: 4.335

Review 10.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.